Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 5/20 | 0.50 |
| ▸ | HTR1A | P08908 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11207435 | 0.90 | HTR7 (0.64) | L3MBTL1ALDH1A1ADRA2AMAPTADRA2B | |
| SCHEMBL684065 | 0.87 | HTR2A (0.52) | SMN1; SMN2HTR7ADORA2BHTR2A | |
| SCHEMBL683646 | 0.87 | HTR2A (0.52) | SMN1; SMN2ADORA2BHTR2A | |
| SCHEMBL684023 | 0.83 | HTR2A (0.58) | L3MBTL1ALDH1A1SMN1; SMN2HTR7ADORA2B | |
| SCHEMBL682820 | 0.83 | L3MBTL1 (0.73) | L3MBTL1HTR7HTR2AHTR1A | |
| SCHEMBL683696 | 0.83 | HTR2A (0.48) | ALDH1A1SMN1; SMN2ADORA2BHTR2A | |
| SCHEMBL684375 | 0.82 | ADORA2B (0.53) | ALDH1A1MAPTSMN1; SMN2ADORA2BHTR2A | |
| SCHEMBL684068 | 0.81 | ADORA2B (0.50) | ADRA2AADRA2CHTR7ADORA2BHTR2A | |
| SCHEMBL684062 | 0.81 | HTR2A (0.52) | ALDH1A1SMN1; SMN2ADORA2BHTR2A | |
| SCHEMBL683640 | 0.79 | HTR2A (0.51) | SMN1; SMN2ADORA2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | L3MBTL1 4624/4885ALDH1A1 1565/4885ADRA2A 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.